骨粗鬆症治療薬のアジア太平洋市場2020-2026:投与経路別(経口、注射、その他)、薬物等級別、地域別

◆英語タイトル:Asia Pacific Osteoporosis Drugs Market By Route of Administration (Oral, Injectable and Other Route of Administration) By Drug Class (Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes) By Country, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT160
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年5月31日
◆ページ数:79
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:中国、日本、インド、韓国、シンガポール、マレーシア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD1,500 ⇒換算¥162,000見積依頼/購入/質問フォーム
Global License(法人利用)USD2,520 ⇒換算¥272,160見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、骨粗鬆症治療薬のアジア太平洋市場について、市場範囲・調査手法、市場概要、投与経路別(経口、注射、その他)分析、薬物等級別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・骨粗鬆症治療薬のアジア太平洋市場規模:投与経路別(経口、注射、その他)
・骨粗鬆症治療薬のアジア太平洋市場規模:薬物等級別
・骨粗鬆症治療薬のアジア太平洋市場規模:地域別
・企業概要
【レポートの概要】

The Asia Pacific Osteoporosis Drugs Market would witness market growth of 5.6% CAGR during the forecast period (2020-2026).

The Asia Pacific market is expected to rise in the coming years in a lucrative CAGR. The region’s rapid growth is expected to be a result of steady R&D spending by the prominent actors and their attempts to market branded and generic medicine at a reasonably low price. The industry is expected to witness intense competition during the forecast period as a result of the increasing incorporation of collaborative strategies among key players to maintain a competitive position. High R&D investment, fusions, and acquisitions, and drug development agreements are the other strategies incorporated.

There has been a noticeable growth in people around the world’s awareness of osteoporosis, which is a noticeable factor in the osteoporosis market. This recognition is primarily a result of numerous steps implemented across different programs and campaigns by public and private associations. For example, the International Foundation for Osteoporosis is an osteoporosis organization.

Due to the increase in R&D investment from major players in advanced novel bisphosphonate drugs, bisphosphonates acquired the major share in the osteoporosis market. Bisphosphonates are also widely used osteoporosis drugs, which stimulates market growth. However, the rank ligand inhibitor segment is expected to have the fastest growth rate during the forecast period, due to the fact that these drugs are used to treat bone metastases by acting as a chemoattractant to the bone for tumor cells that express its receptor, RANK. The RANKL-RANK pathway inhibition thus acts as an ideal treatment for bone metastasis.

Based on Route of Administration, the market is segmented into Oral, Injectable and Other Route of Administration. Based on Drug Class, the market is segmented into Bisphosphonates, Rank Ligand Inhibitors, Parathyroid Hormone Therapy, Calcitonin, Selective Estrogen Inhibitors Modulator (SERM) and Other Drug Classes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers theanalysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC (GSK), Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., Allergan PLC, and Eli Lilly and Company

Scope of the Study
Market Segmentation:

By Route of Administration
• Oral
• Injectable and
• Other Route of Administration

By Drug Class
• Bisphosphonates
• Rank Ligand Inhibitors
• Parathyroid Hormone Therapy
• Calcitonin
• Selective Estrogen Inhibitors Modulator (SERM) and
• Other Drug Classes

By Country
• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific

Companies Profiled
• Amgen, Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline PLC (GSK)
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Allergan PLC
• Eli Lilly and Company

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Osteoporosis Drugs Market, by Route of Administration
1.4.2 Asia Pacific Osteoporosis Drugs Market, by Drug Class
1.4.3 Asia Pacific Osteoporosis Drugs Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Osteoporosis Drugs Market by Route of Administration
3.1 Asia Pacific Oral Market by Country
3.2 Asia Pacific Injectable Market by Country
3.3 Asia Pacific Other Route of Administration Market by Country
Chapter 4. Asia Pacific Osteoporosis Drugs Market by Drug Class
4.1 Asia Pacific Bisphosphonates Market by Country
4.2 Asia Pacific Rank Ligand Inhibitors Market by Country
4.3 Asia Pacific Parathyroid Hormone Therapy Market by Country
4.4 Asia Pacific Calcitonin Market by Country
4.5 Asia Pacific Other Drug Class Market by Country
Chapter 5. Asia Pacific Osteoporosis Drugs Market by Country
5.1 China Osteoporosis Drugs Market
5.1.1 China Osteoporosis Drugs Market by Route of Administration
5.1.2 China Osteoporosis Drugs Market by Drug Class
5.2 India Osteoporosis Drugs Market
5.2.1 India Osteoporosis Drugs Market by Route of Administration
5.2.2 India Osteoporosis Drugs Market by Drug Class
5.3 Japan Osteoporosis Drugs Market
5.3.1 Japan Osteoporosis Drugs Market by Route of Administration
5.3.2 Japan Osteoporosis Drugs Market by Drug Class
5.4 South Korea Osteoporosis Drugs Market
5.4.1 South Korea Osteoporosis Drugs Market by Route of Administration
5.4.2 South Korea Osteoporosis Drugs Market by Drug Class
5.5 Singapore Osteoporosis Drugs Market
5.5.1 Singapore Osteoporosis Drugs Market by Route of Administration
5.5.2 Singapore Osteoporosis Drugs Market by Drug Class
5.6 Malaysia Osteoporosis Drugs Market
5.6.1 Malaysia Osteoporosis Drugs Market by Route of Administration
5.6.2 Malaysia Osteoporosis Drugs Market by Drug Class
5.7 Rest of Asia Pacific Osteoporosis Drugs Market
5.7.1 Rest of Asia Pacific Osteoporosis Drugs Market by Route of Administration
5.7.2 Rest of Asia Pacific Osteoporosis Drugs Market by Drug Class
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.1.4 Recent strategies and developments:
6.1.4.1 Partnerships, Collaborations, and Agreements:
6.1.4.2 Approvals:
6.2 F. Hoffmann-La Roche Ltd.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Research & Development Expense
6.3 GlaxoSmithKline PLC (GSK)
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Research & Development Expense
6.4 Merck & Co., Inc.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Segmental and Regional Analysis
6.4.4 Research & Development Expenses
6.5 Novartis AG
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Recent strategies and developments:
6.5.4.1 Partnerships, Collaborations, and Agreements:
6.6 Pfizer, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Segmental and Regional Analysis
6.6.4 Research & Development Expense
6.7 Sun Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Teva Pharmaceutical Industries Ltd.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expenses
6.9 Allergan PLC
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Segmental and Regional Analysis
6.9.4 Research & Development Expense
6.1 Eli Lilly and Company
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Regional Analysis
6.10.4 Research & Development Expense



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[骨粗鬆症治療薬のアジア太平洋市場2020-2026:投与経路別(経口、注射、その他)、薬物等級別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆